Literature DB >> 7318304

Interaction of chlorpromazine and nortriptyline in patients with schizophrenia.

S Loga, S Curry, M Lader.   

Abstract

Seven male inpatients suffering from acute schizophrenia were treated with chlorpromazine elixir 100mg 8-hourly for 9 weeks. Nortriptyline 50mg 8-hourly was added during weeks 4, 5 and 6. Plasma chlorpromazine concentrations, antipyrine plasma half-life, blood pressure, pulse rate, pupil size, salivation, handwriting and clinical state were measured at weekly intervals. Plasma chlorpromazine concentrations rose when nortriptyline was added, and the antipyrine plasma half-life was prolonged. Blood pressure dropped on institution of chlorpromazine and dropped further with the addition of nortriptyline. The pulse rate rose in a parallel fashion. Pupil size, salivation and handwriting were diminished by chlorpromazine, but hardly affected further by nortriptyline. The addition of nortriptyline dramatically reversed the therapeutic actions of chlorpromazine, mainly through pharmacodynamic interaction. It is concluded that this combination is potentially deleterious, and must be used with care.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7318304     DOI: 10.2165/00003088-198106060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  11 in total

1.  Factor analyses of ratings of schizophrenic behavior.

Authors:  S C GOLDBERG; J O COLE; D J CLYDE
Journal:  Psychopharmacol Serv Cent Bull       Date:  1963-02

2.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

3.  Effects of mode of management on plasma chlorpromazine in psychiatric patients.

Authors:  L Rivera-Calimlim; L Castañeda; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

4.  Physiologic and clinical effects of chlorpromazine and their relationship to plasma level.

Authors:  G Sakalis; S H Curry; G P Mould; M H Lader
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

5.  Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector.

Authors:  S H Curry
Journal:  Anal Chem       Date:  1968-07       Impact factor: 6.986

6.  Studies of depressive symptoms in schizophrenia.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1981-08       Impact factor: 9.319

7.  Impairment of drug metabolism in man by allopurinol and nortriptyline.

Authors:  E S Vesell; G T Passananti; F E Greene
Journal:  N Engl J Med       Date:  1970-12-31       Impact factor: 91.245

8.  Does a plasma level of chlorpromazine help?

Authors:  T Van Putten; P R May; D J Jenden
Journal:  Psychol Med       Date:  1981-11       Impact factor: 7.723

9.  Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man.

Authors:  S Loga; S Curry; M Lader
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

10.  Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man.

Authors:  L F Gram; K F Overo
Journal:  Br Med J       Date:  1972-02-19
View more
  13 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.

Authors:  W A Daniel; M Syrek; A Haduch; J Wójcikowski
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

Review 4.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Clinical pharmacokinetics of clomipramine.

Authors:  A E Balant-Gorgia; M Gex-Fabry; L P Balant
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

6.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

Authors:  Virginia Melis; Iris Usach; Patricia Gandía; José-Esteban Peris
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 8.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

9.  Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline.

Authors:  Iris Usach; Virginia Melis; Patricia Gandía; José-Esteban Peris
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

10.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

Authors:  E K Syvälahti; R Lindberg; J Kallio; M De Vocht
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.